Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix™]: A review of its use as an active immunization against influenza A subtype H5N1 virus

BioDrugs

Volumn 22, Issue 5, 2008, Pages 279-292

  Carter, Natalie J ^a,b   Plosker, Greg L ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug evaluations; Influenza A virus vaccine H5N1, immunogenicity; Influenza A virus vaccine H5N1, therapeutic use; Influenza virus infections, prevention; Research and development

Indexed keywords

AMANTADINE; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; OSELTAMIVIR; PREPANDRIX; RIMANTADINE; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIBODY TITER; CLINICAL TRIAL; CONVULSION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; ECCHYMOSIS; ENCEPHALOMYELITIS; FATIGUE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; LYMPHADENOPATHY; MYALGIA; NEURALGIA; NEURITIS; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SKIN INDURATION; THROMBOCYTOPENIA; VASCULITIS; VIRUS LOAD;

ANIMALS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 51549100095     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200822050-00001     Document Type: Review

References (60)

1. WHO. WHO handbook for journalists: influenza pandemic [online]. Available from URL: http://www.who.int/csr/don/Handbook_influenza_pandem-ic_dec05.pdf [Accessed 2008 Jul 1]
2. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006 Nov 1; 194 Suppl. 2: 111-8
3. WHO. WHO position paper: influenza vaccines. Wkly Epidemiol Rec 2005 Aug 19; 80 (33): 279-87
4. Infectious Diseases Society of America. Pandemic influenza [online]. Available from URL: http://www.cidrap.umn.edu/idsa/influenza/panflu/biofacts/ panflu.html [Accessed 2008 May 9]
5. Kasten MJ, Poland GA. Influenza vaccination and the elderly: pandemic preparedness. Drugs Aging 2008; 25 (3): 179-86
6. Fauci AS. Seasonal and pandemic influenza preparedness: science and counter-measures. J Infect Dis 2006 Nov 1; 194 Suppl. 2: S73-6
7. WHO. Ten things you need to know about pandemic influenza [online]. Available from URL: http://www.who.int/csr/disease/influenza/pandemic10things/ en/print.html [Accessed 2008 May 9]
8. Uyeki TM. Global epidemiology of human infections with highly pathogenic avian influenza A (H5N1) viruses. Respirology 2008 Mar; 13 Suppl. 1: S2-9
9. Ligon BL. Avian influenza virus H5N1: a review of its history and information regarding its potential to cause the next pandemic. Semin Pediatr Infect Dis 2005 Oct; 16 (4): 326-35
10. WHO. Current WHO phase of pandemic alert [online]. Available from URL: http://www.who.int/csr/disease/avian_influenza/phase/en/print.html [Accessed 2008 May 6]
11. Fauci AS. Pandemic influenza threat and preparedness. Emerg Infect Dis 2006 Jan; 12 (1): 73-7
12. Osterhaus ADME. Pre- or post-pandemic influenza vaccine? Vaccine 2007 Jun 28; 25 (27): 4983-4
13. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007 Aug 18; 370 (9587): 580-9
14. Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006 Mar 30; 354 (13): 1343-51
15. WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as human vaccines [online]. Available from URL: http://www.who.int/csr/disease/avian_influenza/guidelines/ H5VaccineVirusUpdate20080214.pdf [Accessed 2008 May 9]
16. WHO/OIE/FAO H5N1 Evolution Working Group. Towards a unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses [online]. Available from URL: http://www.who.int/csr/disease/influenza/nomen.ppt#259,1, Slide 1 [Accessed 2008 May 9]
17. Wu WL, Chen Y, Wang P, et al. Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J Virol 2008 Feb; 82 (4): 1798-807
18. WHO. WHO global influenza preparedness plan: the role of WHO and recommendations for national measures before and during pandemics (WHO/CDS/CSR/GIP/2005.5) [online]. Available from URL: http://www.who.int/csr/ resources/publications/influenza/WHO_CDS_CSR_GIP_2005_5.pdf [Accessed 2008 May 9]
19. Leroux-Roels I, Bernhard R, Gerard P, et al. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 2008 Feb 27; 3 (2): e1665
20. WHO. Global pandemic influenza action plan to increase vaccine supply [online]. Available from URL: http://www.who.int/csr/resources/publications/ influenza/CDS_EPR_GIP_2006_1.pdf [Accessed 2008 Aug 5]
21. Taubenberger JK, Morens DM, Fauci AS. The next influenza pandemic: can it be predicted? JAMA 2007 May 9; 297 (18): 2025-7
22. Poland GA. Vaccines against avian influenza: a race against time. N Engl J Med 2006 Mar 30; 354 (13): 1411-3
23. GlaxoSmithKline Biologicals s.a. Prepandrix suspension and emulsion for injection: European prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/prepandrix/H-822-PI-en.pdf [Accessed 2008 May 22]
24. Chu DW-S, Dramé M, Hwang S-J, et al. Safety and immunogenicity of an AS adjuvanted H5N1 prepandemic influenza vaccine: a phase III study in a large population of Asian adults [abstract]. Xth International Symposium on Respiratory Viral Infections; 2008 Feb 28-Mar 2; Singapore
25. Leroux-Roels I, Bernhard R, Gérard P, et al. Broad and persistant clade 2 cross-reactive immunity induced by an AS adjuvanted clade 1 rH5N1 pandemic influenza vaccine [abstract]. Xth International Symposium on Respiratory Viral Infections; 2008 Feb 28-Mar 2; Singapore
26. Leroux-Roels I, Moris P, Dramé M, et al. Persistence of immune response against clade 1 and clade 2 H5N1 strains induced by an adjuvanted H5N1 clade 1 candidate prepandemic influenza vaccine [abstract]. International Conference on Avian Influenza; 2008 Jan 23-25; Bangkok
27. Moris P, Leroux-Roels I, Dramé M, et al. Heterologous cell-mediated immunity priming using adjuvanted H5N1 candidate vaccine [abstract]. IXth International Symposium on Respiratory Viral Infections; 2007 Mar 3-6; Hong Kong
28. Govorkova EA, Webby RJ, Humberd J, et al. Immunization with reverse-genetic-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challange. J Infect Dis 2006 Jul 15; 194: 159-67
29. Hampson AW. Ferrets and the challenges of H5N1 vaccine formulation. J Infect Dis 2006 Jul 15; 194: 143-5
30. Zitzow LA, Rowe T, Morken T, et al. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J Virol 2002 May; 76 (9): 4420-9
31. Govorkova EA, Rehg JE, Krauss S, et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 2005 Feb; 79 (4): 2191-8
32. Baras B, Stittelaar KJ, Simon JH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 2008 Jan 2; 3 (1): e1401
33. Baras B, Stittelaar K, Simon J, et al. Immunization with low dose adjuvanted split H5N1 pandemic vaccine protects ferrets against homologous challenge [abstract]. IX International Symposium on Respiratory Viral Infections; 2007 Mar 3-6; Hong Kong
34. European Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96) [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/bwp/021496en. pdf [Accessed 2008 Apr 22]
35. US FDA. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines [online]. Available from URL: http://www.fda.gov/cber/gdlns/panfluvac.htm [Accessed 2008 May 11]
36. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03) [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/vwp/471703en.pdf [Accessed 2008 May 11]
37. European Committee for Human Medicinal Products. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context: document EMEA/CHMP/VWP/263499/2006 [online]. Available from URL: http://www.emea.europa. eu/pdfs/human/vwp/26349906enfin.pdf [Accessed 2008 Jul 1]
38. Rümke HC, Bayas JM, de Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008 May 2; 26 (19): 2378-88
39. European Committee for Human Medicinal Products. CHMP assessment report for Prepandrix [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/prepandrix/H-822-en6.pdf [Accessed 2008 Aug 21]
40. US National Institute of Health National Library of Medicine. Evaluate safety and immunogenicity of a pandemic influenza vaccine (GSK1562902A) in adults over 60 years of age (ClinicalTrials.gov identifier: NCT00397215) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00397215? term=NCT00397215〉=1 [Accessed 2008 Jul 17]
41. US National Institute of Health National Library of Medicine. Evaluate safety and immunogenicity of a pandemic influenza vaccine (GSK1562902A) in children (ClinicalTrials.gov identifier: NCT00502593) [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00502593?term=NCT00502593〉=1 [Accessed 2008 Jul 17]
42. Ballesterasparini A, Garces Sanchezno M, Cantarinoni M, et al. Pediatric safety evaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 6-9 years: a phase II study [abstract]. 26th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2008 May 13-17; Graz, Austria
43. Ballester A, Garces-Sanchez M, Planelles Cantarino MV, et al. Pediatric safety evaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3-9 years: a phase II study [abstract]. 13th International Conference on Infectious Diseases; 2008 June 19-22; Kuala Lumpur
44. European Committee for Human Medicinal Products. Summary of positive opinion for Prepandrix [online]. Available from URL: http://www.emea.europa.eu/ pdfs/human/opinion/Prepandrix_6273608en.pdf [Accessed 2008 May 6]
45. WHO. H5N1 avian influenza: timeline of major events [online]. Available from URL: http://www.who.int/csr/disease/avian_influenza/Timeline_080418.pdf [Accessed 2008 May 11]
46. WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO [online]. Available from URL: http://www.who. int/csr/disease/avian_influenza/country/cases_table_2008_04_30/en/print.html [Accessed 2008 May 11]
47. Gambotto A, Barratt-Boyes SM, de Jong MD, et al. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008 Apr 26; 371 (9622): 1464-75
48. van Riel D, Munster VJ, de Wit E, et al. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am J Pathol 2007 Oct; 171 (4): 1215-23
49. Stevens J, Blixt O, Tumpey TM, et al. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006 Apr 21; 312 (5772): 404-10
50. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006 Nov 23; 355 (21): 2186-94
51. Weber DJ, Williams P. Development of an electronic tool to estimate the cost-benefit of stockpiling pre-pandemic influenza vaccine [abstract]. 1st Vaccine Congress; 2007 Dec 9-11; Amsterdam
52. WHO. Experts recommend WHO stockpile up to 150 million doses of avian flu vaccine [online]. Available from URL: http://www.who.int/immunization/sage/ SAGE_note_19_11_07.pdf [Accessed 2008 May 11]
53. El Sahly HM, Keitel WA. Pandemic H5N1 influenza vaccine development: an update. Expert Rev Vaccines 2008 Mar; 7 (2): 241-7
54. WHO. WHO guidance on development of influenza vaccine reference viruses by reverse genetics [online]. Available from URL: http://whqlibdoc.who.int/hq/ 2005/WHO_CDS_CSR_GIP_2005.6.pdf [Accessed 2008 Aug 26]
55. GlaxoSmithKline Biologicals s.a. Daronrix™: European prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/daronrix/H-706-PI-en.pdf [Accessed 2008 May 11]
56. Sanofi Pasteur Inc. Influenza virus vaccine, H5N1 [US prescribing information; online]. Available from URL: http://www.fda.gov/cber/label/ h5n1san041707LB.pdf [Accessed 2008 May 11]
57. GlaxoSmithKline Biologicals s.a. Pandemrix™: European prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/pandemrix/H-832-PI-en.pdf [Accessed 2008 Aug 5]
58. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001 Feb 8; 19 (13-14): 1732-7
59. Bresson J-L, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006 May 20; 367 (9523): 1657-64
60. Allison AC. Squalene and squalane emulsions as adjuvants. Methods 1999 Sep; 19 (1): 87-93